Astria Therapeutics Inc (NASDAQ: ATXS) is 26.95% higher on its value in year-to-date trading and has touched a low of $4.75 and a high of $16.90 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ATXS stock was last observed hovering at around $10.14 in the last trading session, with the day’s loss setting it -0.39%.
Currently trading at $9.75, the stock is -5.26% and -11.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing -3.85% at the moment leaves the stock -12.23% off its SMA200. ATXS registered 96.97% gain for a year compared to 6-month gain of 9.92%. The firm has a 50-day simple moving average (SMA 50) of $11.0104 and a 200-day simple moving average (SMA200) of $11.12455.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -15.29% loss in the last 1 month and extending the period to 3 months gives it a -12.32%, and is -7.14% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.81% over the week and 6.67% over the month.
Astria Therapeutics Inc (ATXS) has around 59 employees, a market worth around $550.23M and $0.00M in sales. Distance from 52-week low is 105.26% and -42.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.92%).
The EPS is expected to grow by 29.93% this year
162.0 institutions hold shares in Astria Therapeutics Inc (ATXS), with institutional investors hold 102.12% of the company’s shares. The shares outstanding are 56.43M, and float is at 48.25M with Short Float at 6.01%. Institutions hold 101.64% of the Float.
The top institutional shareholder in the company is PERCEPTIVE ADVISORS LLC with over 6.49 million shares valued at $59.02 million. The investor’s holdings represent 12.4017 of the ATXS Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 6.05 million shares valued at $55.1 million to account for 11.5778 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 5.04 million shares representing 9.6449 and valued at over $45.9 million, while VR ADVISER, LLC holds 6.9006 of the shares totaling 3.61 million with a market value of $32.84 million.
Astria Therapeutics Inc (ATXS) Insider Activity
The most recent transaction is an insider sale by Morabito Christopher, the company’s Chief Medical Officer. SEC filings show that Morabito Christopher sold 10,000 shares of the company’s common stock on Apr 01 ’24 at a price of $13.59 per share for a total of $0.14 million. Following the sale, the insider now owns 0.0 shares.
Astria Therapeutics Inc disclosed in a document filed with the SEC on Feb 01 ’24 that PERCEPTIVE ADVISORS LLC (Director) bought a total of 2,481,350 shares of the company’s common stock. The trade occurred on Feb 01 ’24 and was made at $12.09 per share for $30.0 million. Following the transaction, the insider now directly holds 4.87 million shares of the ATXS stock.
Still, SEC filings show that on Jan 29 ’24, Morabito Christopher (Chief Medical Officer) disposed off 9,200 shares at an average price of $11.15 for $0.1 million. The insider now directly holds 0 shares of Astria Therapeutics Inc (ATXS).
